默沙东计划于10月1日在美国推出癌症免疫疗法Keytruda的皮下注射版本

金吾资讯
27 Mar

金吾财讯 | 默沙东(MRK)周四表示,计划于10月1日在美国推出癌症免疫疗法Keytruda的皮下注射版本,并预计将在两年内达到新药采用率的峰值。该皮下注射版Keytruda尚未获得美国食品和药物管理局的批准,该局的目标是在9月23日做出决定。Keytruda被批准用于治疗多种类型的癌症,是全球最畅销的处方药,2024年的销售额将近300亿美元。相较于静脉注射,皮下注射将缩短患者获得药物的时间。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10